Promoting genetic counseling for African American women at high risk for breast cancer
Official title: Promoting Genetic Counseling Among African American Women With a Family History of Breast Cancer
Run by University of Illinois at Chicago · NCT04378751 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing whether a special video or a regular brochure can encourage African American women at high risk for breast cancer to attend genetic counseling.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 25 Years and up |
| Sex | Women only |
| Enrollment | 106 (estimated) |
| Sponsor | University of Illinois at Chicago Academic / other |
| Locations | 2 sites (Chicago, Illinois and 1 other locations) |
| Trial ID | NCT04378751 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are African American women aged 25 or older who are classified as high risk for breast cancer and have not previously received genetic counseling.
✕Probably not a fit
Patients who do not identify as African American, are under 25 years old, or have previously received genetic counseling may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research project aims to enhance the attendance of genetic counseling among African American women who are at high risk for breast cancer. Utilizing a randomized control trial design, participants will be assigned to either receive a culturally targeted decision aid video or a standard informational brochure about genetic counseling. The study will assess the effectiveness of these interventions in promoting genetic counseling attendance and will also explore the influence of these interventions on participants' social and familial networks. The study involves a cancer genetic risk assessment as part of the intake process to identify eligible participants.
Why it matters
Potential benefit: If successful, this study could significantly increase the uptake of genetic counseling among high-risk African American women, potentially leading to earlier detection and better management of breast cancer.
How similar studies have gone: Other studies have shown success in using culturally targeted interventions to improve health outcomes in minority populations, suggesting that this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Are female 2. Identify as African American 3. Are age 25 or older 4. Speak and understand English 5. Completed a cancer genetic risk assessment (CGRA) as part of clinic intake 6. Are classified as high risk for developing breast cancer per CGRA 7. Have not previously received genetic counseling Exclusion Criteria: 1. Are not female 2. Do not identify as African American 3. Are age 24 or younger 4. Do not speak and understand English 5. Did not complete a cancer genetic risk assessment (CGRA) as part of clinic intake 6. Are not classified as high risk for developing breast cancer per CGRA 7. Have previously received genetic counseling
Where it's running
-
University of Illinois at Chicago Hospital and Ambulatory Clinics
Chicago, Illinois, United States Recruiting -
UIC Cancer Center
Chicago, Illinois, United States Not yet recruiting
Study contacts
- Principal investigator: Kent Hoskins, MD — University of Illinois at Chicago
- Study coordinator: Kent Hoskins, MD
- Email: khoski@uic.ed
- Phone: 312-355-0496
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Topical 5% minoxidil to boost blood flow and skin‑flap survival during breast reconstruction
This trial will test whether applying 5% topical minoxidil to one breast before bilateral risk‑reducing mastectomy with immediate reconstruction improves blood flow and skin‑flap survival compared with a placebo on the other breast.
-
CDK4/6 inhibitors with endocrine therapy before surgery for HR+/HER2- high-risk early breast cancer
This study tests whether adding a CDK4/6 inhibitor to endocrine therapy before surgery can help guide safer de-escalation of chemotherapy using ctDNA as a marker.
-
ctDNA-guided reduction of chemotherapy using dalpiciclib plus endocrine therapy in high-risk HR+/HER2- early breast cancer
This trial tests whether giving the CDK4/6 drug dalpiciclib with endocrine therapy and using ctDNA results can let some women with early high-risk HR+/HER2- breast cancer skip or reduce chemotherapy.
-
Hetrombopag for secondary prevention of chemotherapy-induced thrombocytopenia in breast cancer
This study tests whether hetrombopag can help breast cancer patients who are at high risk of low platelets during chemotherapy.
-
Robotic nipple sparing mastectomy for breast cancer patients
This study is testing if a robotic surgery method for nipple-sparing mastectomy can safely help breast cancer patients and those at high risk, while also checking how well it works compared to traditional surgery.
-
Robotic-assisted nipple-sparing mastectomy for breast cancer
This study is testing if robotic-assisted nipple-sparing mastectomy is a safe and effective option for women with early-stage breast cancer or those at high risk, compared to traditional surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.